Cargando…
Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project
BACKGROUND: Sponsors that seek to commercialize new drugs apply to the Food and Drug Administration (FDA) which independently analyzes the raw data and reports the results on its website. OBJECTIVES: This study sought to determine if there are differences between the FDA assessments and journal repo...
Autores principales: | Amarilyo, Gil, Furst, Daniel E., Woo, Jennifer M. P., Li, Wen, Bliddal, Henning, Christensen, Robin, Tarp, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725722/ https://www.ncbi.nlm.nih.gov/pubmed/26808309 http://dx.doi.org/10.1371/journal.pone.0147556 |
Ejemplares similares
-
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study
por: Christensen, Anton Wulf, et al.
Publicado: (2015) -
Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis
por: Nielung, Louise, et al.
Publicado: (2015) -
Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol
por: Dossing, Anna, et al.
Publicado: (2014) -
FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)